3 minute read
Oct. 29, 2022

AZD1390: a Brain-Penetrating Ataxia-Telangiectasia Mutated (ATM) Kinase Inhibitor


oral ATM kinase inhibitor Ph. I candidate oncology biochem-based screen. and BBB penetration opt J Pharmacol Exp Ther, Oct 1, 2022 AstraZeneca, Cambridge, UK

Drug Hunter Team

Context. AZD1390 (recently published on by University of Minnesota) is a brain-penetrating Ataxia-Telangiectasia Mutated (ATM) kinase inhibitor under development for brain tumors. The kinase, known for its critical role in the repair of lethal DNA lesions induced by radiotherapy treatment, is considered an attractive target for CNS tumors [...]



Other molecules you may be interested in